Scisparc announces 1-for-26 reverse share split

Tel aviv, israel, sept. 20, 2023 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it will conduct a reverse share split of its issued and outstanding ordinary shares, no par value, at a ratio of 1-for-26. the company's ordinary shares will begin trading on the nasdaq capital market on a post-split basis at the market open on september 28, 2023, under the company's existing trading symbol "sprc".
SPRC Ratings Summary
SPRC Quant Ranking